Cargando…

Sensitivity of a Ribavirin Resistant Mutant of Hepatitis C Virus to Other Antiviral Drugs

BACKGROUND: While ribavirin mono-therapy regimens have minimal effect on patients with chronic hepatitis C virus (HCV) infections, they can be efficacious when combined with interferon. Clinical studies show that interferon-free combination therapies containing ribavirin are also efficacious, sugges...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mihalik, Kathleen B., Feigelstock, Dino A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764029/ https://www.ncbi.nlm.nih.gov/pubmed/24040153 http://dx.doi.org/10.1371/journal.pone.0074027

Ejemplares similares

Selection of hepatitis C virus resistant to ribavirin
por: Feigelstock, Dino A, et al.
Publicado: (2011)

Increased susceptibility of Huh7 cells to HCV replication does not require mutations in RIG-I
por: Feigelstock, Dino A, et al.
Publicado: (2010)

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection
por: Feld, Jordan J., et al.
Publicado: (2016)

Use of ribavirin in viruses other than hepatitis C. A review of the evidence()
por: Ramírez-Olivencia, German, et al.
Publicado: (2019)

Hepatitis C Virus and Antiviral Drug Resistance
por: Kim, Seungtaek, et al.
Publicado: (2016)

Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection
por: Kuntzen, Thomas, et al.
Publicado: (2016)

Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals
por: Guardigni, Viola, et al.
Publicado: (2017)

Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
por: Mathur, Poonam, et al.
Publicado: (2018)

Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters
por: Doyle, Mary-Anne, et al.
Publicado: (2019)

The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis
por: Liu, Jun-Ying, et al.
Publicado: (2012)

Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus
por: Mayor, Jennifer, et al.
Publicado: (2021)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Triple Combination Antiviral Drug (TCAD) Composed of Amantadine, Oseltamivir, and Ribavirin Impedes the Selection of Drug-Resistant Influenza A Virus
por: Hoopes, Justin D., et al.
Publicado: (2011)

Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin
por: Derudas, Marco, et al.
Publicado: (2010)

Antiviral drugs against hepatitis C virus
por: Rehman, Sidra, et al.
Publicado: (2011)

Establishment of Hepatitis C Virus RNA-Replicating Cell Lines Possessing Ribavirin-Resistant Phenotype
por: Satoh, Shinya, et al.
Publicado: (2015)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
por: Tang, L., et al.
Publicado: (2018)

Modeling Ribavirin‐Induced Anemia in Patients with Chronic Hepatitis C Virus
por: Wu, LS, et al.
Publicado: (2016)

Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection
por: Gallacher, Jennifer, et al.
Publicado: (2023)

Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance
por: Beaucourt, Stéphanie, et al.
Publicado: (2014)

Inhibitors of Peptidyl Proline Isomerases As Antivirals in Hepatitis C and Other Viruses
por: Striker, Rob, et al.
Publicado: (2014)

Counteracting Quasispecies Adaptability: Extinction of a Ribavirin-Resistant Virus Mutant by an Alternative Mutagenic Treatment
por: Perales, Celia, et al.
Publicado: (2009)

Extinction of Hepatitis C Virus by Ribavirin in Hepatoma Cells Involves Lethal Mutagenesis
por: Ortega-Prieto, Ana M., et al.
Publicado: (2013)

Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy
por: Krishnan, Sheeja M., et al.
Publicado: (2011)

Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy
por: Melendez-Mena, Daniel, et al.
Publicado: (2021)

In vitro antiviral activity of ribavirin against severe fever with thrombocytopenia syndrome virus
por: Lee, Myung Jin, et al.
Publicado: (2017)

The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C
por: Abenavoli, Ludovico, et al.
Publicado: (2011)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

High antiviral activity of NS5A inhibitor ABT‐530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection
por: Poordad, Fred, et al.
Publicado: (2016)

Hepatitis C virus quasispecies in chronically infected children subjected to interferon–ribavirin therapy
por: Figlerowicz, Magdalena, et al.
Publicado: (2010)

Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance
por: Douglas, Mark W., et al.
Publicado: (2020)

Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir
por: Won, Juhee, et al.
Publicado: (2022)

Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review
por: Mucenic, Marcos, et al.
Publicado: (2019)

Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C
por: Delvaux, Nathália, et al.
Publicado: (2015)

Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals
por: Izumi, Namiki, et al.
Publicado: (2018)

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents
por: Damiani, Giovanni, et al.
Publicado: (2018)

Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
por: Razonable, Raymund R.
Publicado: (2011)

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections
por: Izhari, Mohammad Asrar
Publicado: (2023)

Genetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus Ribavirin
por: Cuevas, José Manuel, et al.
Publicado: (2008)

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis
por: Kim, Kyung Hoon, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pve5thoh64irj5t5699r7oq080